For example, immunologists reported last fall that patients injected with an experimental DNA-based malaria vaccine showed not just malaria antibodies but also significant levels of killer T cells.
I saw excellence in research and institutional capacities, where 11 centres across the region are now conducting phase 3 trials of a potentially revolutionary malaria vaccine.
These two foundations, as well as others from the "malaria vaccine funders' group" (see below), are investing resources into priority Roadmap activities.
Which is why the work in Bagamoyo tesed whether the malaria vaccine could be integrated into African countries’ existing system for inoculating infants with a group of established vaccines.
